Seres Therapeutics, Inc. (MCRB) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low17.6·High17.6
P/B Ratio
↓
5.15
↓-75% vs avg
5yr avg: 20.62
30Y Low3.0·High56.1
ROE
↑
1.0%
↓+101% vs avg
5yr avg: -133.6%
30Y Low-352%·High1%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Seres Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $80M | $129M | $179M | $605M | $764M | $2.0B | $195M | $184M | $410M | $394M | $826M |
| Enterprise Value | $141M | $190M | $250M | $605M | $633M | $1.9B | $175M | $106M | $383M | $351M | $752M |
| P/E Ratio → | -0.48 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 5.27 | 58.85 | 5.66 | 6.52 | 12.78 | 18.12 | — |
| P/B Ratio | 5.15 | 9.37 | — | 56.13 | 5.81 | 11.19 | — | — | 6.76 | 2.97 | 4.02 |
| P/FCF | — | — | — | — | — | — | — | — | — | 17.59 | — |
| P/OCF | — | — | — | — | 114.22 | — | — | — | — | 8.98 | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 4.37 | 56.59 | 5.07 | 3.74 | 11.93 | 16.11 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | 15.63 | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
ROE of 1.0% is modest.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | -172.7% | 100.0% | -239.5% | -178.7% | -276.7% | — |
| Operating Margin | — | — | — | — | -44.5% | -265.3% | -208.3% | -354.8% | -284.7% | -426.5% | — |
| Net Profit Margin | — | — | — | — | -45.2% | -268.3% | -203.7% | -350.0% | -278.4% | -420.7% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.0% | 1.0% | — | -351.6% | -42.8% | -141.0% | — | -1563.8% | -92.5% | -54.2% | -61.3% |
| ROA | 0.1% | 0.1% | -32.2% | -71.1% | -18.8% | -37.5% | -55.6% | -63.8% | -38.7% | -37.4% | -32.8% |
| ROIC | -180.9% | -180.9% | -806.1% | -2440.3% | -96.6% | -429.2% | — | — | -112.0% | -63.2% | — |
| ROCE | -67.7% | -67.7% | -74.6% | -67.2% | -22.7% | -46.0% | -87.2% | -84.9% | -45.7% | -41.4% | -34.5% |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $61M ($92M total debt minus $31M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.65 | 6.65 | — | 15.08 | 0.37 | 0.23 | — | — | 0.15 | 0.08 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 4.41 | — | -0.04 | -0.99 | -0.43 | — | — | -0.45 | -0.33 | -0.36 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -1.95 | — |
| Interest Coverage | — | — | -14.81 | -29.89 | -22.16 | -30.14 | -143.18 | -85.57 | -57.48 | -95.81 | -98.84 |
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.94x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.28x to 0.94x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | 0.94 | 1.78 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 | 19.01 |
| Quick Ratio | 0.94 | 0.94 | 1.48 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 | 19.01 |
| Cash Ratio | 0.75 | 0.75 | 1.30 | 2.12 | 3.53 | 5.46 | 2.06 | 2.04 | 4.74 | 6.34 | 18.78 |
| Asset Turnover | — | — | — | — | 0.41 | 0.10 | 0.26 | 0.23 | 0.17 | 0.08 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 103.15 | 18.88 | — | — | — | — |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Seres Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | 5.7% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $8M | $6M | $5M | $5M | $4M | $3M | $2M | $2M | $2M | $1M |
Peer Comparison
Compare MCRB with 7 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MCRBYou | $80M | -0.5 | — | — | — | — | 1.0% | -180.9% | — |
 PHGE | $83B | -4.3 | — | — | — | — | -130.2% | -305.2% | — |
 ARMP | $420M | -22.2 | — | — | -565.4% | -820.2% | — | -44.2% | — |
 EVGN | $7M | -0.3 | — | — | 39.8% | -255.4% | -75.8% | -102.4% | — |
 SYBX | $7M | -0.3 | — | — | 100.0% | -511875.0% | -84.3% | -205.7% | — |
 AZTR | $2M | -0.1 | — | — | — | — | -0.6% | -0.8% | — |
 TOVX | $252100 | -0.0 | — | — | — | — | -87.3% | -142.7% | — |
 ELAB | $23875 | -0.0 | — | — | 72.8% | -75.7% | -119.1% | -82.7% | — |
| Healthcare Median | — | 23.2 | 14.9 | 19.0 | 65.8% | -6.4% | -36.7% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MCRB vs PHGE
See how MCRB stacks up against sector leader BiomX Inc..
Start ComparisonFrequently Asked Questions
What is Seres Therapeutics, Inc.'s P/E ratio?
Seres Therapeutics, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
What is Seres Therapeutics, Inc.'s ROE?
Seres Therapeutics, Inc.'s return on equity (ROE) is 1.0%. The historical average is -107.3%.
Is MCRB stock overvalued?
Based on historical data, Seres Therapeutics, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.